Jacobio Pharmaceuticals Group Co., Ltd. Stock Price

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. Its clinical stage candidates include Glecirasib (JAB-21822), a KRAS G12C inhibitor under various stage studies for indications, such as NSCLC, Multi-tumors basket, and CRC; Sitneprotafib (JAB-3312), an SHP2 inhibitor that is in Phase III trials for NSCLC indication; JAB-23E73, a Pan-KRAS inhibitor for indications, including PDAC, CRC, NSCLC and solid tumor; JAB-BX600 KRAS G12D inhibitor; JAB-8263 BET inhibitor; JAB-2485 Aurora A inhibitor, JAB-30355 p53 Y220C mutation, JAB-BX102 CD73 monoclonal antibody inhibitor. The company also develops IND-enabling candidates comprising JAB-BX467, JAB-BX600 KRAS G12D inhibitor, and JAB-BX700 for solid tumor indications. The company has a collaboration agreement with AstraZeneca AB to develop and commercialize Pan-KRAS inhibitor JAB-23E7. Jacobio Pharmaceuticals Group Co., Ltd. was founded in 2015 and is headquartered in Beijing, China.